Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification

Exploring resistance mechanisms in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) upon disease progression on EGFR tyrosine kinase inhibitors (TKIs) has been an area of great interest as it may lead to effective next-line treatment strategies. Here we report a case of emergent MET ampl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Viola W, Schrock, Alexa B, Ali, Siraj M, Ou, Sai-Hong Ignatius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419586/
https://www.ncbi.nlm.nih.gov/pubmed/30881166
http://dx.doi.org/10.2147/LCTT.S190403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419586/
https://www.ncbi.nlm.nih.gov/pubmed/30881166
http://dx.doi.org/10.2147/LCTT.S190403

Ejemplares similares